فاس نيوز ميديا جريدة الكترونية جهوية تعنى بشؤون و أخبار جهة فاس مكناس – متجددة على مدار الساعة
The Moroccan Agency for Medicines and Health Products has issued an urgent decision to withdraw specific batches of the pharmaceutical product “Aureomycin 1%,” a widely used eye ointment, after discovering a defect in the product’s appearance during routine monitoring operations conducted by the agency to ensure drug quality.
The agency, in its statement, clarified that it issued immediate instructions to the pharmaceutical company “Promopharma,” the drug’s manufacturer, to urgently withdraw the affected batches from the market, in order to ensure consumer safety and compliance with approved pharmaceutical standards.
The agency specified the non-compliant batches, which bear the serial numbers: 22043, 22046, and 23001. It confirmed that the withdrawal process includes all distribution channels, including wholesalers, pharmacies, public health institutions’ drug supply management, and private medical clinics.
The agency stressed the need to immediately recover the affected quantities and requested “Promopharma” to prepare a detailed final report documenting the withdrawal process, with an accurate comparison between distributed and recovered quantities. It also requested an official record confirming the destruction of the withdrawn batches to ensure safe disposal.
In its commitment to transparent communication with healthcare professionals, the agency mandated the company to prepare an official letter explaining the reasons for the withdrawal, to be submitted to the agency for approval before distribution.
This measure is part of the preventive policy followed by the Moroccan Agency for Medicines and Health Products, which prioritizes citizen safety through continuous monitoring of the quality of medicines circulating in the national market.
